Lower LDL Is Better In New ACC/AHA Guidelines, Making The Case For Add-Ons To Statins
The guidelines give specific guidance about LDL cholesterol goals, recommending Esperion’s bempedoic acid and PCSK9 inhibitors from Amgen and Regeneron on top of statins in many cases, but evidence review concluded before Repatha’s primary prevention data.
Scrip - March 18, 2026

With FDA Approval, Icotyde Wades Into Competitive Psoriasis Market
The drug is the first oral IL-23 receptor antagonist to clear the US FDA. Johnson & Johnson and partner Protagonist Therapeutics are banking on its convenience as well as efficacy and safety to make the drug competitive.
Scrip - March 18, 2026

A Fast Win For Alfasigma With Lynavoy Approval
The company licensed worldwide rights to the IBAT inhibitor from GSK just days ahead of the drug’s US FDA approval for cholestatic pruritus associated with primary biliary cholangitis.
Scrip - March 18, 2026

Precision Takes New Tack To Gene Editing To Halt Duchenne
The company aims to restore near-normal muscle regrowth with its novel in vivo gene therapy PBGENE-MD, which it is now pursuing alone.
Scrip - March 18, 2026

Cell & Gene Therapy’s Future: Activating Large-Scale Commercial Promise
Cell and gene therapy is entering a new phase, shifting beyond oncology and rare diseases toward broader autoimmune and neurological indications, but progress will hinge on speed across regulation, manufacturing, financing and clinical development, the Advanced Therapies UK conference heard.
Scrip - March 18, 2026

Paratek Continues Its Portfolio Expansion With Radius Takeout
Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.
Scrip - March 18, 2026

Sandoz Divests Generics Portfolio In Sub-Saharan Africa To Strides
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region
Scrip - March 18, 2026

Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss
Near-term focus for Rhythm will be on the upcoming regulatory decision for Imcivree in acquired hypothalamic obesity, with an FDA decision expected in the coming days.
Scrip - March 18, 2026

Kanaph, IMbiologics Shine In Otherwise Idle Q1 Korea IPO Market
Kanaph Therapeutics and IMbiologics launched successful offerings in the IPO-scarce Korean market in the first quarter, as investors become more selective in their targets.
Scrip - March 18, 2026

Pfizer, Roche Looking Beyond Simple Licensing In China Deals
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Scrip - March 18, 2026

Almirall Eyes China Dermatology Assets Beyond Simcere Partnership
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Scrip - March 18, 2026

JenaValve’s Trilogy Becomes First FDA-Approved TAVR Treatment For Aortic Regurgitation
The FDA approved JenaValve’s Trilogy HeartValve for treating severe aortic regurgitation, marking it as the first TAVR device for this condition in the US. The approval, which followed promising clinical results, is significant for patients with limited options due to high surgical risks.
Medtech Insight - March 18, 2026

Amplifon Buys GN Hearing For €2.3Bn, Taking Aim At Sonova And Demant
The combined entity will employ more than 20,000 people across more than 100 countries, hold close to 3,000 patents, and bring together more than 700 R&D professionals.
Medtech Insight - March 18, 2026

Injuries, Death, Linked To Intuitive Surgical Stapler Used With Da Vinci Robotic System
The US FDA has issued an early alert concerning Intuitive Surgical staplers used during various procedures with the da Vinci Surgical System. The company is instructing customers to stop using the devices.
Medtech Insight - March 18, 2026

California EPR Stakeholder Reports Due May 31 Will Shape Fees Under Program
Circular Action Alliance, the Producer Responsibility Organization in charge of implementing California’s EPR program, urges single-use packaging producers to comply with an upcoming May 31 deadline, which will shape proposed fees.
HBW Insight - March 19, 2026

From Potential ‘Bloodbath’ To Promo Warnings: Semaglutide’s India Reckoning
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
Generics Bulletin - March 18, 2026

The Blockbuster US Brands Set To Fade In 2026
Merck, Johnson & Johnson, AstraZeneca and Roche are among the big pharma manufacturers that will face substantial exclusivity losses in the US this year.
Generics Bulletin - March 18, 2026

Celltrion Completes US Tocilizumab Rollout With Subcutaneous Launch
Celltrion has added a subcutaneous formulation to its Avtozma biosimilar in the US, completing a dual-presentation strategy aimed at matching Actemra and improving uptake in a market where biosimilar penetration has so far remained limited.
Generics Bulletin - March 18, 2026

Pressure Builds On Generics Supply Chain As War In Iran Continues
With concerns building over the potential impact on medicines supply of the war in Iran, Medicines for Europe and Medicines UK have offered a measured assessment of current supply-chain pressures and the potential for future disruption.
Generics Bulletin - March 18, 2026

Sandoz Adds Early-Stage Biosimilars In Expanded Samsung Bioepis Deal
Sandoz has struck a new deal with Samsung Bioepis covering up to five early-stage biosimilars, expanding an existing alliance as the Swiss-based firm ramps up investment, reorganizes its business and targets a wave of upcoming biologics loss-of-exclusivity opportunities.
Generics Bulletin - March 18, 2026

Regulatory Departments Must Prepare For The Digital-First Era In Europe
Digitalization is expected to reform the European pharmaceutical industry. But it will also change perceptions towards technology and current regulatory skillsets.
Generics Bulletin - March 18, 2026

NRx Moves Closer To US Ketamine Approval On Clean Bioequivalence Review
NRx says the FDA has identified no bioequivalence deficiencies in its Ketafree ANDA, clearing a key hurdle ahead of a potential mid-2026 decision as the firm pursues parallel generic and innovative ketamine strategies.
Generics Bulletin - March 18, 2026

Execs On The Move: February 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026

An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026